Chronic obstructive pulmonary disease (COPD) is associated with acute and chronic pulmonary as well as systemic inflammation [1]. Anti-inflammatory treatments, such as inhaled corticosteroids (ICS) and oral roflumilast, are recommended for COPD patients [2]. These drugs are effective agents for the prevention of COPD exacerbations and improvement of lung function and have various effects on health status, but they are associated with adverse events, the most concerning being pneumonia (ICS) and diarrhoea (roflumilast).

Peripheral eosinophil count as a biomarker for the management of COPD: not there yet / Rabe, Klaus F.; Beghe', Bianca; Fabbri, Leonardo M.. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 50:5(2017), pp. 1-4. [10.1183/13993003.02165-2017]

Peripheral eosinophil count as a biomarker for the management of COPD: not there yet.

Bianca Beghé;Leonardo M. Fabbri
2017

Abstract

Chronic obstructive pulmonary disease (COPD) is associated with acute and chronic pulmonary as well as systemic inflammation [1]. Anti-inflammatory treatments, such as inhaled corticosteroids (ICS) and oral roflumilast, are recommended for COPD patients [2]. These drugs are effective agents for the prevention of COPD exacerbations and improvement of lung function and have various effects on health status, but they are associated with adverse events, the most concerning being pneumonia (ICS) and diarrhoea (roflumilast).
2017
22-nov-2017
50
5
1
4
Peripheral eosinophil count as a biomarker for the management of COPD: not there yet / Rabe, Klaus F.; Beghe', Bianca; Fabbri, Leonardo M.. - In: EUROPEAN RESPIRATORY JOURNAL. - ISSN 0903-1936. - 50:5(2017), pp. 1-4. [10.1183/13993003.02165-2017]
Rabe, Klaus F.; Beghe', Bianca; Fabbri, Leonardo M.
File in questo prodotto:
File Dimensione Formato  
1702165.full.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 325.08 kB
Formato Adobe PDF
325.08 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1148502
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact